Dr. Stephen Rennard
Richard and Margaret Larson Professor of Pulmonary Research, University of Nebraska Medical Center, Omaha, NE
Professor Stephen Rennard completed undergraduate training in Folklore and Mythology at Harvard College, obtained his MD degree from Baylor College of Medicine, trained in Internal Medicine at Washington University and then did research and Pulmonary training at the National Institutes of Health. He was Chief of the Pulmonary Division at University of Nebraska Medical Centre, Omaha, from 1984 until 1997 and remains the Richard and Margaret Larson Research Professor at the University. He has been a Fellow, Homerton College, University of Cambridge since 2016. His research has focused on mechanisms of tissue remodelling and repair and clinical studies particularly related to chronic obstructive pulmonary disease and smoking cessation. He has received numerous awards including the Career Research Award of the Department of Internal Medicine, the Scientist Laureate Award of UNMC, and the Outstanding Research and Creativity Award of the University of Nebraska. He has served on the American Board of Internal Medicine, Pulmonary Committee, Board of Directors for the American Lung Association, the American Thoracic Society, the Alpha-1 Foundation and the COPD Foundation, on the initial committee that prepared the GOLD Guidelines and was an author of the COPD Foundation Guide for the Diagnosis and Management of COPD, and he currently co-chairs the COPD Biomarker Qualification Consortium.
From August 2015 until November 2019, he worked at AstraZeneca, Cambridge, UK. Starting as Chief Clinician Scientist in the Clinical Discovery Unit of Early Clinical Development (ECD), he became head of that Unit in 2016. Stephen was appointed Head of IMED Early Clinical Development in November 2017 and was promoted to Senior Vice President 2018. The ECD had responsibility for clinical trials from first time in man through Phase 2 including study design, biostatistics, clinical pharmacology and disease modelling and operations across therapeutic areas. During his time at AZ, Stephen led initiatives in patient segmentation, novel clinical trial design and outcomes and human target validation. During his tenure, the ECD initiated novel operations models, clinical designs, target validation and decision making approaches achieving industry leading timelines and success rates. He returned to UNMC in 2019 where he has been developing wearable technologies for medical diagnosis and screening and advanced designs for translational clinical trials in emphysema.